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Abstract
Background: Bronchiolitis is the most common cause of lower respiratory tract illness in infancy,
and hospital admission rates appear to be increasing in Canada and the United States. Inhaled beta
agonists offer only modest short-term improvement. Trials of racemic epinephrine have shown
conflicting results. We sought to determine if administration of racemic epinephrine during hospital
stay for bronchiolitis improved respiratory distress, was safe, and shortened length of stay.
Methods: The study was a randomized, double-blind controlled trial of aerosolized racemic
epinephrine compared to salbutamol every one to 4 hours in previously well children aged 6 weeks
to ≤ 2 years of age hospitalized with bronchiolitis. The primary outcome was symptom
improvement as measured by the Respiratory Distress Assessment Instrument (RDAI); secondary
outcomes were length of stay in hospital, adverse events, and report of symptoms by structured
parental telephone interview one week after discharge.
Results: 62 children with a mean age of 6.4 months were enrolled; 80% of children had Respiratory
Syncytial Virus (RSV). Racemic epinephrine resulted in significant improvement in wheezing and the
total RDAI score on day 2 and over the entire stay (p < 0.05). The mean LOS in the epinephrine
arm was 2.6 days (95% CI 2, 3.2) v. 3.4 days in those in the salbutamol group (95% CI 2.6, 4.2) (p
> 0.05). Adverse events were not significantly different in the two arms. At one week post-
discharge, over half of parents reported that their child still had a respiratory symptom and 40%
had less than normal feeding.
Conclusion: Racemic epinephrine relieves respiratory distress in hospitalized infants with
bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with
bronchiolitis as identified by parents persists for at least one week after hospital discharge in most
infants.
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Bronchiolitis accounts for up to 60% of all lower respira-
tory tract illness in the first year of life [1] and up to 32%
of hospitalizations for lower respiratory tract illness in
this age group [2]. The incidence of hospitalisation for
bronchiolitis in infancy has increased in both the United
States [3] and Canada [4] in the last two decades, and a
100% increase in first time hospitalisation for lower respi-
ratory tract illness in children under two years has been
noted in northern Europe [5].
Bronchiolitis is characterized by tachypnea and wheezing
due to obstruction of small airways, and therefore treat-
ment has often included use of beta and alpha agonists
delivered by aerosol in addition to supportive care. A sys-
tematic review of randomised clinical trials of the efficacy
of beta-agonist aerosols suggests they offer only modest
short term improvement [6]. Alpha agonist stimulation of
the sympathetic nervous system would be expected to
reduce capillary leakage by constricting precapillary arteri-
oles, reducing hydrostatic pressure and consequently
bronchial mucosal edema [7]. Since Wohl and Chernick
first suggested this intervention in 1978 [8], multiple
studies and systematic reviews [9-11] have been pub-
lished. While there is evidence that acute symptoms of
bronchiolitis measured in the short term may improve
with epinephrine, these reviews have called for more stud-
ies assessing longer-term outcomes such as duration of
stay, and that are clinically relevant to parents, clinicians
and the health care system.
We report a randomised controlled trial of aerosolised
epinephrine compared to salbutamol throughout hospi-
tal stay in infants with bronchiolitis to assess daily clinical
improvement (respiratory distress, feeding), length of
hospital stay and adverse events, and outcomes by paren-
tal report one week after discharge to the community.
Methods
This study was a randomized, double blind controlled
trial of racemic epinephrine (Vaponefrin solution 2.25%,
Aventis Pharma Inc, Laval, PQ) compared to control
(salbutamol, Ventolin, GlaxoSmithKline Inc., Missis-
sauga, ON) in children requiring hospitalization for man-
agement of bronchiolitis.
Patient population
Eligible children were aged greater than 6 weeks to ≤ 2
years with a clinical diagnosis of bronchiolitis by the
admitting physician. Wheezing had to be present on phys-
ical examination and was defined as a high-pitched, musi-
cal, continuous respiratory sound. Only patients admitted
for management of bronchiolitis were eligible. The parent
or guardian had to be able cooperate with study require-
ments (ability to speak, read and write English, have a tel-
ephone at home and not expected to move within the next
month). The participating institutions were the IWK
Health Centre in Halifax, Nova Scotia and the Saint John
Regional Hospital (SJRH) in Saint John, New Brunswick.
The IWK is a university-affiliated primary and tertiary-care
pediatric hospital with an urban population of 300,000
and is a referral center for the Maritime provinces (popu-
lation 2 million) of Canada. SJRH serves a rural-urban
population of 200,000.
Children were not eligible for enrollment if they had had
a previous diagnosis of asthma, were critically ill, or had
chronic pulmonary or cardiac disease. Other exclusion cri-
teria included: allergy to sodium metabisulfite, presence
of tachycardia exceeding 200 beats per minute, or use of
glucocorticoids, sympathomimetic amines or monoam-
ine oxidase inhibitor therapy.
Informed consent was obtained from the parent or guard-
ian prior to enrolment. The protocol was approved by the
Ethics Review Board at both participating institutions.
Study procedures
Study enrolment occurred in sequential winter respiratory
seasons (November to April) from 1999 to 2002. Families
were approached regarding study participation in the
emergency department or within 24 hours of admission.
Research nurses were available to enroll patients between
8 am and 8 pm.
Treatment allocation was determined by randomization,
performed in blocks of four by the pharmacy department
using a computer-generated random numbers table.
Study drug was packaged in identical multidose vials
labeled "study drug" with a code number. Both salbuta-
mol and racemic epinephrine are clear, colorless liquids
that are indistinguishable [12]. Participants were allo-
cated to racemic epinephrine, 0.5 mls of 2.25% (Vapone-
frin solution, Aventis Pharma, Montreal Quebec) or
salbutamol respirator solution (Pharmel Inc., Montreal,
Canada) by aerosol. Study drug was administered every
one to four hours or more frequently at the request of the
attending physician. Study drug was delivered by a wall
flowmeter-nebulizer with face mask (Hospitak Inc.,
Farmingdale, NC) with oxygen at 5 to 7 L/min. A standard
order sheet was used to ensure consistency of trial meth-
odology. Salbutamol was given in 3 ml normal saline at a
dosage of 1.5 mg for children weighing more than 10 kg,
1.25 mg for children >6 kg and < 10 kg, and 0.75 mg for
those weighing less than 6 kgs. The heart rate was meas-
ured continuously during each aerosol and for one hour
after. The heart rate, vomiting, presence of tremors or pal-
lor were recorded in the health record by the bedside
nurse at the end of every aerosol and one hour post
aerosol.Page 2 of 7
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Baseline demographic data collected at study entry
included inclusion and exclusion criteria, age, gender,
concomitant medications and other illnesses. The car-
egiver/parent was asked to describe the child's feeding pat-
tern (normal, less than normal, unable to feed). At the
time of study enrolment and then daily (every morning)
thereafter the study nurse measured oxygen saturation
and wheezing and retractions using the Respiratory Dis-
tress Assessment Instrument (Table 1) [13], which was the
primary outcome measure of the study. Oxygen saturation
was measured using a pulse oximeter (Nellcor Pulse Oxi-
meter, Nellcor Puritan Bennet Inc., Pleasanton, CA) with
the infant in a quiet state after breathing room air for at
least 10 minutes. If the oxygen saturation went below
85%, the measurement was halted. At the daily assess-
ment, the study nurse interviewed caregivers and reviewed
the health record to determine if adverse events were
present (vomiting, tremors, pallor), the feeding pattern
and recorded the maximum daily heart rate for that 24-
hour period.
During the first two study enrolments, it was noted that a
bright red nasal discharge was observed in some study
participants, and interpreted by bedside nurses as bloody
nasal discharge. This discoloration of nasal mucous was
found to be a known effect of administration of aero-
solized epinephrine, which is caused by the oxidation of
the sulphite stabilizer. This effect was not known to the
investigators at the time of study design and is not in the
drug monograph, but has been reported in a recent trial of
epinephrine in the emergency department setting [14].
Because this could lead to unblinding of treatment alloca-
tion, an amendment to the study protocol was made for
all subsequent patients whereby the bedside nurse wiped
the nose of study participants after each study drug
administration and immediately before the study nurse
performed the daily respiratory assessment.
A nasopharyngeal aspirate for Respiratory Syncytial virus
(RSV) antigen was routinely done in participating hospi-
tals to determine appropriate placement for infection con-
trol purposes. At the discretion of the attending physician,
some children had respiratory tract samples submitted for
respiratory virus culture (RSV, influenza, parainfluenza,
adenovirus).
A secondary outcome measure was duration of hospital
stay, measured using a method previously validated by
the Pediatric Investigators Collaborative Network on
Infections in Canada studies of hospitalized children with
RSV infection [15]. Each day the study nurse assessed
which of four reasons accounted for ongoing hospitaliza-
tion 1) patient receiving drug treatment for bronchiolitis
2) patient receiving oxygen supplementation or
parenteral fluids because of bronchiolitis 3) patient hos-
pitalized because of underlying (pre-existing) illness only
or 4) awaiting transport home or uncertain home envi-
ronment. Only those days on which the reason for hospi-
talization were one or more of receiving medication for
bronchiolitis (1) or oxygen supplementation or
parenteral fluids because of bronchiolitis (2), were
recorded as valid hospital days. Discharge timing, counted
as the time the decision was made to discharge home, was
at the discretion of the attending physician. Study person-
nel had no involvement in discharge planning and did
not impose any discharge criteria.
All parents/guardians were telephoned seven days after
hospital discharge by a research assistant to collect data
about the child's convalescence: respiratory symptoms
(retractions, wheezing), feeding pattern (normal, less
Table 1: Respiratory Distress Assessment Instrument (From: Lowell DI, Lister G, Von Kloss H, McCarthy P. Wheezing in infants: the 
response to epinephrine. Pediatrics 1987; 87:939-45.)
0 1 2 3 4 Maximum Points
Wheezing
Expiration None End 1/2 3/4 All 4
Inspiration None Part All ... ... 2
Location None Segmental Diffuse ... ... 2
Retractions
Supraclavicular None Mild Moderate Marked ... 3
Intercostal None Mild Moderate Marked ... 3
Subcostal None Mild Moderate Marked 3
Total ... ... ... 17
* Within each variable (wheezing, retractions) the subscores are summed to give a total score. The maximum total points for wheezing is 8 and for 
retractions is 9.Page 3 of 7
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cation (shakiness, tremors, pallor," other problems") and
whether they had required a visit to a physician or to the
emergency department or hospital. The interviewer read
closed-ended questions from a standard script.
Adverse events were collected during the hospital stay and
during the post-discharge telephone call. The event was
described and categorized according to severity (mild,
moderate, severe), outcome (recovered fully, recovered
with sequelae, ongoing, death) and relationship to study
drug (related, probably or possibly related, unrelated,
unable to classify). Mild adverse events were defined as
"awareness of signs and symptoms, easily tolerated and
require no interventions", moderate as "discomfort suffi-
cient enough to interfere with normal activities and/or
result in some sort of intervention" and severe as " inabil-
ity to perform normal activities, distressing and/or inca-
pacitating and definitely require intervention and/or
medical attention."
The sample size was calculated to detect a difference in the
RDAI score between day one and day three. The estimated
sample size for a two-sample comparison of proportions
of each group that achieved the four-unit difference was
with a probability of type one error of 0.05 and type 2
error of 0.8 was 33 infants per group. The standard devia-
tions were based on previously reported changes in RDAI
in bronchiolitis [13].
Analysis
All randomized children were considered in the analysis.
All analyses were performed using SAS 8.02 software (SAS
Institute Inc., Cary, USA). Proportions and exact binomial
intervals were calculated for discrete variables and com-
parisons between treatment groups were made using the
Fisher's exact test. Summary statistics (mean, median,
standard deviation, minimum and maximum) were cal-
culated for continuous variables and comparisons were
made between treatment groups using the Wilcoxon rank-
sum test. Comparisons of trend across time were made
using repeated measures analysis of variances. The RDAI
was treated as a continuous measure. P-values less than or
equal to 0.05 were considered statistically significant.
Results
Sixty-two children were enrolled with 31 in each treat-
ment arm. Ten were enrolled from the Saint John site and
52 from the Halifax site. All participants completed in-
hospital follow-up but the parent of one child in the
epinephrine group could not be contacted for the one-
week post-discharge telephone call. The mean age of par-
ticipants was 6.4 months. RSV was identified in nasopha-
ryngeal samples of 81.5% of children randomized to
epinephrine and 78.6% of those randomized on salbuta-
mol. The two groups were similar at baseline; characteris-
tics at enrolment are seen in Table 2. On admission, only
15% of infants had a normal feeding pattern; 83% had
decreased feeding by parental/caregiver report and 7%
were unable to feed. 245 children were screened who did
not enroll: 46 did not meet inclusion criteria and in 34
parents refused consent. The rest were ineligible because
of exclusion criteria. The most commons reason for exclu-
sion was previous diagnosis of asthma (n = 58) and previ-
ous administration of systemic steroids (n = 44).
Racemic epinephrine resulted in a significant improve-
ment in wheezing compared to salbutamol on day 2 (p =
0.01) and over the entire hospital stay (p = 0.01) (Table
3), but not on other days. The total RDAI (wheezing and
retractions) in children receiving racemic epinephrine was
also significantly better on the second hospital day and
over the entire stay (p = 0.02). On the third hospital day a
significant difference in oxygen saturation was observed
in children receiving racemic epinephrine compared to
those receiving salbutamol (96.20% v. 93.80%, 98.80 v.
92.00 p = 0.03) but this difference was not significant
when the two groups were compared over the entire hos-
pital stay or on other days.
The mean length of stay for children randomized to the
racemic epinephrine group was 2.60 days (95% CI 2.00,
3.20) and 3.40 days for those randomized to salbutamol
(95% CI 2.60, 4.20) (p > 0.05). No significant differences
in length of stay or RDAI scores were seen when children
confirmed as having RSV infection were compared to
those without RSV.
There was no difference in wheezing score, total retraction
score, total respiratory score oxygen saturation or duration
of stay by study site.
Any adverse event (mild, moderate, severe) was reported
in 45.20% (14/31) of children who received epinephrine
compared to 51.60% (16/31) of those who received salb-
utamol (p > 0.05). There was one severe adverse event
(fever greater than 39°C rectal), judged unrelated to study
medication, which occurred in a child on salbutamol.
Tremors and pallor were more common in children
receiving racemic epinephrine than in those on salbuta-
mol, but these differences were not statistically significant
(19.40% (6/31) v. 9.70% (3/31) and 19.40% (6/31) v.
6.50% (2/31) respectively). Vomiting occurred in 19.4%
(6/31) of those receiving epinephrine and 25.8% (8/31)
of those on salbutamol; this difference was not statisti-
cally significant.
At the follow-up telephone call, one week after discharge
over 60% of infants had at least one ongoing respiratory
symptom (Table 4) and most were still not considered toPage 4 of 7
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nificant differences in outcomes at the follow-up phone
call were identified.
Discussion
In this study, treatment of bronchiolitis with aerosolised
racemic epinephrine over the course of a child's hospital
stay was associated with improvement in respiratory
symptoms, but did not result in a statistically significant
difference in hospital length of stay. Although previous
reports have found that nebulized epinephrine results in
short-term clinical improvement in bronchiolitis [12,16-
21], its effect on duration of hospital stay or need for
admission is less clear. Two of four randomised clinical
trials in the emergency department setting using 1 to 3
doses of epinephrine have found a difference in admis-
sion rate [12,19] and two have not [22,23]. It is possible
that small reductions in length of stay could be detected
by larger trials than those conducted thus far. Our study is
only the second [24] in which nebulized racemic epine-
phrine was provided throughout the hospital admission.
Other trials have administered one to three doses spaced
on one day only. One might expect that short-term
improvement could lead to the clinician's judgement that
admission was not necessary. Two [20,21] of four ran-
domised trials [24,25] have suggested that length of stay
in hospital is abbreviated in children receiving epine-
phrine. The subgroup of children that might benefit from
this therapy is not clear and larger trials will be necessary
to identify if and when administrations of nebulized
epinephrine during hospitalisation results in patient ben-
efit. Our study supports the thesis that while airway
edema may be improved following administration of
racemic epinephrine it is not sustained and does not alter
the natural history of bronchiolitis in infants. The inflam-
matory process initiated by RSV or other respiratory
viruses is unaffected and mucous secretion and edema
recurs after the effect of epinephrine has dissipated.
We choose salbutamol as a control for epinephrine
because it was the local standard of care at the time our
trial was designed and it was considered unethical to with-
Table 2: Characteristics of children less than two years of age admitted to hospital with bronchiolitis by treatment group, at 
enrolment.
Outcome Racemic Epinephrine Salbutamol
Male 45.20 % 64.50 %
Age (median) 5.49 months 3.32 months
RDAI total 7.35 (95% CI 6.52, 8.19) 8.29 (95% CI 7.24, 9.34)
Wheezing 4.23 (95% CI 3.60, 4.85) 5.06 (95% CI 4.28, 5.85)
Retractions 3.13 (95% CI 2.64, 3.62) 3.23% (95% CI 2.71, 3.74)
Oxygen saturation (mean) 94.6 % 93.5 %
Abnormal feeding pattern (less than normal or not feeding) 90% ((95% CI 7.35, 97.9) 80% (95% CI 61.4, 92.3)
RSV positive 81.5% (61.9, 93.7) 78.6 (95% CI 59, 91.7)
RDAI = Respiratory Distress Assessment Instrument, CI = confidence interval
Table 3: Respiratory Distress Assessment Instrument scores by hospital day in children with bronchiolitis randomized to aerosolized 
racemic epinephrine or salbutamol.
Hospital Day 
(Number of 
children in hospital 
for that duration)








0 (n = 62) 4.23 5.06 3.13 3.23 7.35 8.29
1 (n = 58) 2.04 3.70 1.64 1.64 3.68 6
2 (n = 40) 1.59 2.65 1.06 1.06 2.65 4.13
3 (n = 22) 2.09 2.73 1.09 1.09 3.18 4.27
4 (n = 9) 2.75 4.00 1.75 1.75 4.5 6.4
5 (n = 9) 2.00 2.60 0.75 0.75 2.75 4.2Page 5 of 7
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benefit was likely minimal [6]. Other randomized trials of
epinephrine in hospitalized children have used as the
control normal saline [22,25], salbutamol [21] or both
[24].
Interestingly we noted a risk to unblinding of treatment
allocation early in our trial, by the oxidation of the sul-
phite preservatives, which turn mucous red or brown in
recipients of racemic epinephrine. We implemented
measures to avoid unblinding, but could find no mention
of this event in previous studies of epinephrine in bron-
chiolitis. If future trials of racemic epinephrine are con-
ducted, study design should carefully address this
possibility and consider using another formulation of
epinephrine. Patel et al questioned study personnel and
ward staff after completion of their trial and found no dif-
ference in the proportion of correct guesses as to alloca-
tion by treatment group [24].
Hospital admission for bronchiolitis occurs when the
infant has significant respiratory distress or is unable to
feed because of the work of breathing. By this point in the
evolution of bronchiolitis, lower respiratory tract inflam-
mation is well established and may be difficult to alter.
Perhaps for this reason, trials of steroid therapy in infants
hospitalized for bronchiolitis have shown no benefit [11].
Length of hospital stay or avoidance of hospital admis-
sion is a salient outcome measure for intervention trials of
epinephrine because institutional care represents the larg-
est component of direct expenditures (over 60%) for
bronchiolitis [26]. Morbidity associated with bronchioli-
tis persisted for at least one week after hospital discharge
in our population. Reducing costs and morbidity due to
bronchiolitis may require more than one intervention,
each at specific times during the illness. For example
Schuh et al demonstrated a reduction in hospitalization in
infants with bronchiolitis treated with dexamethasone (1
mg/kg) in the emergency department [27]. Bisgaard et al
demonstrated a reduction in post-RSV symptomatology,
principally cough, in infants treated with montelukast
within the first week of illness [28]. All of these treat-
ments, if their efficacy were borne out in larger trials,
would reduce health care costs associated with this
ubiquitous infection. Such studies will need to be large to
capture clinically significant outcomes.
Use of racemic epinephrine multiple times over several
days was not associated with significant adverse events
compared to salbutamol. Epinephrine is a potent adrener-
gic agonist with potential cardiovascular side effects
including tachycardia or bradycardia and hypertension. In
the doses used for bronchiolitis such adverse events have
not been reported. Given that short-term improvement
may occur and its favourable safety profile, it seems rea-
sonable to use aerosolized racemic epinephrine selectively
for infants with acute distress to decrease the work of
breathing or to avoid assisted ventilation.
Conclusion
Racemic epinephrine relieves respiratory distress (wheez-
ing, retractions) in infants hospitalized for management
of bronchiolitis and is safe but does not abbreviate hospi-
tal stay. Morbidity associated with bronchiolitis as identi-
fied by parents persists for at least one week after hospital
discharge in most infants.
Table 4: Prevalence of respiratory symptoms and drug-related adverse events one week after discharge in children randomized to 
aerosolized racemic epinephrine or salbutamol during their hospital stay for bronchiolitis.
Clinical event as reported by 
parent or guardian
Percentage of children with symptom at one week post-discharge phone 
call (absolute numbers)*
P value for comparison of 
proportions
Racemic epinephrine Salbutamol
Breathing difficulty 20.00 (6/30) 19.4 (6/31) 1.00
Wheezing 56.7 (17/30) 67.7 (21/31) 0.43
Chest retractions 13.3 (4/30) 25.8 (8/31) 0.33
Feeding pattern:
Normal feeding 50 (15/30) 54.8 (17/31) 0.80
Less than normal 50 (15/30) 41.9 (13/31) 0.61
Unable to feed 0 (0/31) 3.2 (1/31) 1.00
Vomiting 20 (6/30) 35.5 (11/31) 0.25
Tremors 0 (0/31) 0 (0/31) N/A
Pallor 13.3 (4/30) 6.5 (2/31) 0
Has had a visit to a physician 23.3 (7/30) 19.4 (6/31) 0.42
Has visited an emergency 
department or been hospitalized
3.3 (1/30) 3.2 (1/31) 1.00
N/A = not applicable; * Not mutually exclusivePage 6 of 7
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